State of the art/science: Visual methods and information behavior research

This panel reports on methodological innovation now underway as information behavior scholars begin to experiment with visual methods. The session launches with a succinct introduction to visual methods by Jenna Hartel and then showcases three exemplar visual research designs. First, Dianne Sonnenwald presents the "information horizon interview" (1999, 2005), the singular visual method native to the information behavior community. Second, Anna Lundh (2010) describes her techniques for capturing and analyzing primary school children's information activities utilizing video recordings. Third, Nancy Fried Foster (Foster & Gibbons, 2007) reports how students, staff and faculty members produce maps, drawings, and photographs as a means of contributing their specialist knowledge to the design of library technologies and spaces at the University of Rochester. Altogether, the panel will present a collage of innovative visual research designs and engage the associated epistemological, theoretical, methodological, and empirical issues. All speakers will have 15 minutes and be timed to allow a minimum of 30 minutes for audience questions, comments, and discussion. Upon the conclusion attendees will have gained: knowledge of the state of the art/science of visual methods in information behavior research; an appreciation for the richness the approach brings to the specialty; and a platform to take new visual research designs forward

Staphylococcus aureus nasal colonization in HIV-seropositive and HIV-seronegative drug users

Nasal colonization plays an important role in the pathogenesis of Staphylococcus aureus infections. To identify characteristics associated with colonization, we studied a cross-section of a well-described cohort of HIV-seropositive and -seronegative active and former drug users considered at risk for staphylococcal infections. Sixty percent of the 217 subjects were Hispanic, 36% were women, 25% actively used injection drugs, 23% actively used inhalational drugs, 23% received antibiotics, and 35% were HIV-seropositive. Forty-one percent of subjects had positive nasal cultures for S. aureus. The antibiotic susceptibility patterns were similar to the local hospital's outpatient isolates and no dominant strain was identified by arbitrarily primed polymerase chain reaction (AB-PCR). Variables significantly and independently associated with colonization included antibiotic use (odds ratio [OR] = 0.37; confidence interval [CI] = 0.18-0.77), active inhalational drug use within the HIV-seropositive population (OR = 2.36; CI = 1.10-5.10) and female gender (OR = 1.97; CI = 1.09-3.57). Characteristics not independently associated included injection drug use, HIV status, and CD4 count. The association with active inhalational drug use, a novel finding, may reflect alterations in the integrity of the nasal mucosa. The lack of association between HIV infection and S. aureus colonization, which is contrary to most previous studies, could be explained by our rigorous control for confounding variables or by a limited statistical power due to the sample sizes

Physical therapy and exercise interventions in Huntington's disease: a mixed methods systematic review protocol

Review question/objective: : The review seeks to evaluate the effectiveness of physical therapy and exercise interventions in Huntington's disease (HD). The review question is: What is the effectiveness of physiotherapy and therapeutic exercise interventions in people with HD, and what are patients’, families’ and caregivers’ perceptions of these interventions? Review question/objective: The specific objectives are: Review question/objective: This mixed methods review seeks to develop an aggregated synthesis of quantitative, qualitative and narrative systematic reviews on physiotherapy and exercise interventions in HD, in an attempt to derive conclusions and recommendations useful for clinical practice and policy decision-making

Differences in the progress of the biopesticide revolution between the EU and other major crop-growing regions

The five-year value in the compound annual growth rate of the biopesticides sector is predicted to be 16% by 2017 and to produce a global market worth $US 10 billion. Despite this, several impediments occur within the EU that negatively affect biopesticide research and innovation. At present, there are fewer biopesticide-active substances registered in the EU compared with the United States, India, Brazil and China. The relatively low level of biopesticide research in the EU (6880 ISI papers) versus the United States (18839), India (9501) and China (7875) relates to the greater complexity of EU-based biopesticide regulations compared with these other countries. In this light, it is worth noting that tensions may exist between regulators that emphasise the beneficial nature of biopesticides in environmentally friendly crop management and those that adopt a more technologically based approach dependent on a chemical-pesticide-driven model. Compared with the other aforementioned countries, far fewer biopesticide products are available in the EU market, mainly as a direct result of the severe regulatory factors present there. The extent to which this trend will continue depends largely on a range of interacting political and/or regulatory decisions that influence environmentally friendly agricultural industries. (c) 2017 Society of Chemical Industr

Infectious Diseases

This article is made available for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.Pulmonary infections are caused by a wide range of pathogenic microorganisms, including bacteria, viruses, fungi, and parasites. The most common lung infections in immunocompetent hosts are caused by pyogenic bacteria (e.g., Streptococcus pneumoniae), common respiratory viruses, and mycoplasma. These infections are usually diagnosed by clinical and microbiologic studies, including cultures and serology tests. Lung biopsy is rarely used in these diagnoses. Patients with life-threatening pneumonia, especially those who are immunocompromised, are more likely to undergo lung biopsy to rule out unusual infections not easily diagnosed using conventional microbiologic methods and for which treatment strategies may be different. Pathogens more likely to be diagnosed using lung biopsy for which there are characteristic pathologic changes are highlighted in this chapter and listed in Table 4.1